208 related articles for article (PubMed ID: 26660679)
1. Rates of Treatment Eligibility in Follow-Up of Patients with Chronic Hepatitis B (CHB) Across Various Clinical Settings Who Were Initially Ineligible at Presentation.
Uribe LA; Nguyen N; Kim L; Trinh HN; Wong C; Wong C; Nguyen LH; Nguyen MH
Dig Dis Sci; 2016 Feb; 61(2):618-25. PubMed ID: 26660679
[TBL] [Abstract][Full Text] [Related]
2. Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy.
Nguyen NH; Nguyen V; Trinh HN; Lin B; Nguyen MH
Clin Gastroenterol Hepatol; 2013 May; 11(5):565-71. PubMed ID: 23333662
[TBL] [Abstract][Full Text] [Related]
3. Alternative Therapies for Chronic Hepatitis B Patients With Partial Virological Response to Standard Entecavir Monotherapy.
Chaung KT; O'Brien C; Ha NB; Nguyen NH; Trinh HN; Nguyen MH
J Clin Gastroenterol; 2016 Apr; 50(4):338-44. PubMed ID: 26646801
[TBL] [Abstract][Full Text] [Related]
4. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
Li N; Xu JH; Yu M; Wang S; Si CW; Yu YY
World J Gastroenterol; 2015 Nov; 21(43):12421-9. PubMed ID: 26604649
[TBL] [Abstract][Full Text] [Related]
5. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
[TBL] [Abstract][Full Text] [Related]
6. Undertreatment of Asian chronic hepatitis B patients on the basis of standard guidelines: a community-based study.
Zhang S; Ristau JT; Trinh HN; Garcia RT; Nguyen HA; Nguyen MH
Dig Dis Sci; 2012 May; 57(5):1373-83. PubMed ID: 22466077
[TBL] [Abstract][Full Text] [Related]
7. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
Cai S; Yu T; Jiang Y; Zhang Y; Lv F; Peng J
Clin Exp Med; 2016 Aug; 16(3):429-36. PubMed ID: 26164128
[TBL] [Abstract][Full Text] [Related]
8. Low treatment rates in patients meeting guideline criteria in diverse practice settings.
Kim LH; Nguyen VG; Trinh HN; Li J; Zhang JQ; Nguyen MH
Dig Dis Sci; 2014 Sep; 59(9):2091-9. PubMed ID: 25060778
[TBL] [Abstract][Full Text] [Related]
9. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.
Wang CC; Tseng KC; Peng CY; Hsieh TY; Lin CL; Su TH; Tseng TC; Hsu CS; Lin HH; Kao JH
J Gastroenterol Hepatol; 2013 Jan; 28(1):46-50. PubMed ID: 22989322
[TBL] [Abstract][Full Text] [Related]
10. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
[TBL] [Abstract][Full Text] [Related]
11. Simplifying Treatment Criteria in Chronic Hepatitis B: Reducing Barriers to Elimination.
Wong RJ; Kaufman HW; Niles JK; Kapoor H; Gish RG
Clin Infect Dis; 2023 Feb; 76(3):e791-e800. PubMed ID: 35594550
[TBL] [Abstract][Full Text] [Related]
12. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
[TBL] [Abstract][Full Text] [Related]
13. A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase≤2 upper limit of normal.
Gao S; Fan YC; Zhao J; Sun FK; Han J; Zhao ZH; Wang K
Liver Int; 2014 Aug; 34(7):e229-37. PubMed ID: 24112455
[TBL] [Abstract][Full Text] [Related]
14. Adherence to chronic hepatitis B treatment guideline recommendations for laboratory monitoring of patients who are not receiving antiviral treatment.
Juday T; Tang H; Harris M; Powers AZ; Kim E; Hanna GJ
J Gen Intern Med; 2011 Mar; 26(3):239-44. PubMed ID: 20978862
[TBL] [Abstract][Full Text] [Related]
15. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability.
Kim GA; Lim YS; An J; Lee D; Shim JH; Kim KM; Lee HC; Chung YH; Lee YS; Suh DJ
Gut; 2014 Aug; 63(8):1325-32. PubMed ID: 24162593
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients.
Jung KS; Park JY; Chon YE; Kim HS; Kang W; Kim BK; Kim SU; Kim do Y; Han KH; Ahn SH
J Gastroenterol; 2016 Aug; 51(8):830-9. PubMed ID: 26687058
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients.
Kim HJ; Cho JY; Kim YJ; Gwak GY; Paik YH; Choi MS; Koh KC; Paik SW; Yoo BC; Lee JH
Korean J Intern Med; 2015 Jan; 30(1):32-41. PubMed ID: 25589833
[TBL] [Abstract][Full Text] [Related]
18. HBV-DNA level at 6 months of entecavir treatment predicts HBeAg loss in HBeAg-positive chronic hepatitis B patients.
Peng CY; Hsieh TC; Hsieh TY; Tseng KC; Lin CL; Su TH; Tseng TC; Lin HH; Wang CC; Kao JH
J Formos Med Assoc; 2015 Apr; 114(4):308-13. PubMed ID: 24315616
[TBL] [Abstract][Full Text] [Related]
19. Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir.
Hadziyannis SJ; Sevastianos V; Rapti I; Vassilopoulos D; Hadziyannis E
Gastroenterology; 2012 Sep; 143(3):629-636.e1. PubMed ID: 22659218
[TBL] [Abstract][Full Text] [Related]
20. Liver Complications in Untreated Treatment-Ineligible versus Treated Treatment-Eligible Patients with Hepatitis B.
Huang DQ; Lee DH; Le MH; Le A; Yeo YH; Trinh HN; Chung M; Nguyen V; Johnson T; Zhang JQ; Wong C; Wong C; Li J; Cheung R; Nguyen MH
Dig Dis; 2023; 41(1):115-123. PubMed ID: 36070707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
